{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:13:05Z","timestamp":1783415585501,"version":"3.54.6"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s13555-023-01094-9","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T19:02:47Z","timestamp":1707332567000},"page":"533-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation Analysis of Clinician- and Patient-Reported Outcomes Among Japanese Adults with Atopic Dermatitis"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"umin000022623","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-0355","authenticated-orcid":false,"given":"Hidehisa","family":"Saeki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5121-0134","authenticated-orcid":false,"given":"Yoko","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Etoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-2482","authenticated-orcid":false,"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2184-0597","authenticated-orcid":false,"given":"Satoshi","family":"Teramukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8744-8411","authenticated-orcid":false,"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-8787","authenticated-orcid":false,"given":"Kazuhiko","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"issue":"10","key":"1094_CR1","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1111\/1346-8138.16527","volume":"49","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ohya Y, Furuta J, et al. English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. J Dermatol. 2022;49(10):e315\u201375.","journal-title":"J Dermatol"},{"issue":"1","key":"1094_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2133.2004.05696.x","volume":"150","author":"N Barbier","year":"2004","unstructured":"Barbier N, Paul C, Luger T, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150(1):96\u2013102.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1094_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/1346-8138.14787","volume":"46","author":"N Katoh","year":"2019","unstructured":"Katoh N, Saeki H, Kataoka Y, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): baseline characteristics, treatment history and disease burden. J Dermatol. 2019;46(4):290\u2013300.","journal-title":"J Dermatol"},{"issue":"5","key":"1094_CR4","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/bjd.13662","volume":"172","author":"YA Leshem","year":"2015","unstructured":"Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353\u20137.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1094_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.17243","volume":"180","author":"KR Patel","year":"2019","unstructured":"Patel KR, Singam V, Vakharia PP, et al. Measurement properties of three assessments of burden used in atopic dermatitis in adults. Br J Dermatol. 2019;180(5):1083\u20139.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1094_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.anai.2020.03.006","volume":"125","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Lei D, Yousaf M, et al. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: a validation study. Ann Allergy Asthma Immunol. 2020;125(1):78\u201383.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"1094_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1094_CR8","first-page":"69","volume":"24","author":"MM Mukaka","year":"2012","unstructured":"Mukaka MM. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69\u201371.","journal-title":"Malawi Med J"},{"issue":"9","key":"1094_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/1346-8138.16485","volume":"49","author":"N Katoh","year":"2022","unstructured":"Katoh N, Saeki H, Kataoka Y, et al. Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate-to-severe atopic dermatitis: two-year data from the ADDRESS-J disease registry. J Dermatol. 2022;49(9):903\u201311.","journal-title":"J Dermatol"},{"issue":"2","key":"1094_CR10","doi-asserted-by":"publisher","first-page":"adv00402","DOI":"10.2340\/00015555-3751","volume":"101","author":"M de Bruin-Weller","year":"2021","unstructured":"de Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1094_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/bjd.19751","volume":"185","author":"KS Thomas","year":"2021","unstructured":"Thomas KS, Apfelbacher CA, Chalmers JR, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol. 2021;185(1):139\u201346.","journal-title":"Br J Dermatol"},{"key":"1094_CR12","unstructured":"National Institute for Health and Care Excellence (NICE). Dupilumab for treating moderate to severe atopic dermatitis. Technology appraisal guidance [TA534]. 2018. https:\/\/www.nice.org.uk\/guidance\/ta534. Accessed August 2023."},{"issue":"2","key":"1094_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/1346-8138.15730","volume":"48","author":"K Miyano","year":"2021","unstructured":"Miyano K, Tsunemi Y. Current treatments for atopic dermatitis in Japan. J Dermatol. 2021;48(2):140\u201351.","journal-title":"J Dermatol"},{"issue":"8","key":"1094_CR14","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s11136-017-1551-3","volume":"26","author":"A Konnopka","year":"2017","unstructured":"Konnopka A, Koenig HH. The \u201cno problems\u201d-problem: an empirical analysis of ceiling effects on the EQ-5D 5L. Qual Life Res. 2017;26(8):2079\u201384.","journal-title":"Qual Life Res"},{"issue":"4","key":"1094_CR15","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1111\/ajd.13719","volume":"62","author":"M Mizuno","year":"2021","unstructured":"Mizuno M, Horiguchi G, Teramukai S, et al. Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab. Australas J Dermatol. 2021;62(4):e504\u20139.","journal-title":"Australas J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01094-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01094-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01094-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T18:20:31Z","timestamp":1708712431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01094-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1094"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01094-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"16 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hidehisa Saeki has received lecture fees from AbbVie, Eli Lilly Japan, Japan Tobacco, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Otsuka, Sanofi, Taiho, and Torii Pharmaceutical; and scholarship donations from Esai, Maruho, Taiho Pharma, and Tokiwa. Yoko Kataoka reports honoraria for lectures and contract research grants from Sanofi; and research grants from AbbVie, Eli Lilly, LEO Pharma, Maruho, Otsuka, and Pfizer. Takafumi Etoh has received honoraria for lectures from Kyowa Kirin and Maruho. Norito Katoh has received honoraria for lectures from AbbVie, Celgene Japan, Eli Lilly Japan, Janssen Pharmaceuticals, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Sanofi, and Taiho Pharma; and research grants from AbbVie, Eli Lilly Japan, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Sanofi, Sun Pharma, and Taiho Pharma. Satoshi Teramukai has received honoraria for lectures from Bayer, Chugai Pharmaceutical, and Nipro; a research grant from Nippon Boehringer Ingelheim and Sun Contact Lens; and consultant fees from Atworking, Daiichi Sankyo, Gunze, Kaneka, Kringle Pharma, NapaJen Pharma, Sanofi, Solasia Pharma, Sysmex, and Takeda. Yuki Tajima, Hiroyuki Fujita, and Kazuhiko Arima are Sanofi K.K. employees, and may hold stock and\/or stock options in the company. Marius Ardeleanu is an employee and shareholder of Regeneron Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the provisions of the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice (ICH GCP) guideline, and applicable regulatory requirements. The protocol was reviewed and approved by the following institutional review boards\/ethics committees: Asai Dermatology Clinic Institutional Review Board (Central IRB); Kyoto Prefectural University of Medicine Medical Ethics Review Committee; Nippon Medical School Ethics Committee; Medical Research Ethics Committee\/Commissioned Research Review Committee, Osaka Habikino Medical Center; Medical Ethics Committee, Tokyo Teishin Hospital; Epidemiological Research Ethics Review Committee, Graduate School of Biomedical and Health Sciences, Hiroshima University; Ethics Committee, Tokyo Women's Medical University; Epidemiology and Observational Research Ethics Review Committee, The University of Tokyo Graduate School of Medicine; Intervention and Observational Research Ethics Review Committee, Osaka University Graduate School of Medicine; University of Yamanashi School of Medicine Ethics Committee; Clinical Research Ethics Review Committee, Dokkyo Medical University Saitama Medical Center. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}